Search

Background Adenomyosis (AM) is a common and difficult gynecological disease, but its specific mechanism has not been fully elucidated. Traditional Chinese Medicine (TCM) has certain advantages in the treatment of AM, preliminary studies have shown that Guilou compound-releasing intrauterine system can significantly reduce the proliferation and invasion ability of endometrial cells in rats with AM model. Objective To investigate the effect of Guilou compound on the migration and invasion of human adenomyosis derived cells (AMDC), and study its effect on Rho/ROCK signaling pathway. Methods The experiment was completed from October 2021 to April 2023 in Central Laboratory of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine. The CCK-8 assay was used to detect AMDC cell viability and screen the optimal drug concentration. AMDC were treated with Guilou compound (50 and 100 mg/L), and the cell migration viability was detected by scratch assay, and cell invasion ability was detected by Transwell assay. The expression of RhoA, RhoB, RhoC, ROCK1, and ROCK2 at protein and mRNA levels was detected by Western Blotting/RT-qPCR assay. In the Rescue experiment, AMDC were treated with agonist U-46619 (1 μmol/L) and Guilou compound (100 mg/L), and the protein expression of RhoA, RhoB, RhoC, ROCK1, and ROCK2 was detected by Western Blotting. Results Compared with the control group, the survival rate of AMDC treated with 100 mg/L mass concentration of Guilou compound was not significantly decreased (P>0.05), which was the optimal drug concentration without affecting the cell viability, 50 and 100 mg/L mass concentrations of Guilou compound were selected for subsequent experiments. Compared with the control group, the migration and invasion ability of AMDC in the Guilou compound (50 mg/L, 100 mg/L) group was significantly inhibited (P0.05) . Conclusion Guilou compound can effectively inhibit the migration and invasion ability of AMDC with the optimal drug concentration of 100 mg/L that does not affect the cell viability, Guilou compound can reverse the up-regulation of U-46619 on the protein expression of RhoA, RhoC, ROCK1 and ROCK2, thus inhibiting the the continuous progression of ectopic lesions of AM, which may be closely related to the regulation of Rho/ROCK pathway.

Heavy metal pollution has been a magnificent concern for a long period. A novel magnetic material, MnO2/PDA@Fe3O4, was prepared in this paper. With the assistance of multiple characterization methods, it was confirmed that polydopamine coated the magnetic nucleus and acted as a dense intermediate layer for MnO2 attachment. Having superior adsorption performance, MnO2/PDA@Fe3O4 could remove heavy metal cations efficiently no matter in single or mixed systems. The maximum adsorption capacities calculated by the Langmuir model for Pb(II), Cu(II), and Cd(II) were 295.01 mg/g, 130.30 mg/g, and 115.16 mg/g, respectively. In mixed systems, the adsorbent showed obvious selectivity for Pb(II). And the variation of Cu(II) concentration was more responsible for Pb(II) adsorption than that of Cd(II). The kinetic and thermodynamic data revealed that the polluted ions immobilizations by MnO2/PDA@Fe3O4 were chemisorption and were endothermic, entropy increase, spontaneous process. The presence of humic acid and coexisting ions induced only a very limited interference. In addition, MnO2/PDA@Fe3O4 maintained excellent adsorption performance and stability after five cycles of adsorption and removed 98.33% Pb(II) and 71.24% Cu(II) from actual water, respectively. This study confirmed that the MnO2/PDA@Fe3O4 had great potential and broad prospects to remediate the heavy metal contaminants in water. [ABSTRACT FROM AUTHOR]

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours, arising mainly from the interstitial cells of Cajal (ICCs) of the gastrointestinal tract. As radiotherapy and chemotherapy are generally ineffective for GISTs, the current primary treatment is surgical resection. However, surgical resection is not choice for most patients. Therefore, new therapeutic strategies are urgently needed. Targeted therapy, represented by tyrosine kinase inhibitors (TKIs), and immunotherapy, represented by immune checkpoint inhibitor therapies and chimeric antigen receptor T-cell immunotherapy (CAR-T), offer new therapeutic options in GISTs and have shown promising treatment responses. In this review, we summarize the molecular classification and immune microenvironment of GISTs and discuss the corresponding targeted therapy and immunotherapy options. This updated knowledge may provide more options for future therapeutic strategies and applications in GISTs., Competing Interests: Author MY was employed by the company Guangzhou KingMed Diagnostics Group Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Yu, Yu, Luo, Zhang, Zeng, Chen, Lin, Chen and Wang.)